Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
EBIT MarginEBITDA MarginEBT MarginFCF MarginInterest Coverage RatioNet MarginOperating MarginReturn on SalesTimes Interest Earned

Candel Therapeutics (CADL) Return on Assets (2021 - 2023)

Candel Therapeutics' Return on Assets history spans 3 years, with the latest figure at 0.66% for Q3 2023.

  • For Q3 2023, Return on Assets fell 27.0% year-over-year to 0.66%; the TTM value through Sep 2023 reached 0.66%, down 27.0%, while the annual FY2022 figure was 0.42%, 2.0% down from the prior year.
  • Return on Assets for Q3 2023 was 0.66% at Candel Therapeutics, down from 0.57% in the prior quarter.
  • Across five years, Return on Assets topped out at 0.28% in Q4 2021 and bottomed at 0.66% in Q3 2023.
  • The 3-year median for Return on Assets is 0.39% (2022), against an average of 0.43%.
  • The largest annual shift saw Return on Assets dropped -1bps in 2022 before it dropped -27bps in 2023.
  • A 3-year view of Return on Assets shows it stood at 0.28% in 2021, then plummeted by -53bps to 0.43% in 2022, then plummeted by -56bps to 0.66% in 2023.
  • Per Business Quant, the three most recent readings for CADL's Return on Assets are 0.66% (Q3 2023), 0.57% (Q2 2023), and 0.48% (Q1 2023).